Long-term effects of iloperidone on cerebral dopamine receptor subtypes

Synapse

Volumn 72, Issue 10, 2018, Pages

  Kee Choi, Yong ^a   Tarazi, Frank I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

atypical antipsychotics; dopamine receptors; iloperidone; schizophrenia; typical antipsychotics

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; ILOPERIDONE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; DORSAL STRIATUM; DORSOLATERAL FRONTAL CORTEX; DOSE RESPONSE; ENTORHINAL CORTEX; HIPPOCAMPUS; MALE; MEDIAL PREFRONTAL CORTEX; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR AUTORADIOGRAPHY; SPRAGUE DAWLEY RAT;

EID: 85051521869     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.22039     Document Type: Article

References (43)

1. Abi-Dargham, A., & Laruelle, M. (2005). Mechanisms of action of second generation antipsychotic drugs in schizophrenia: Insights from brain imaging studies. European Psychiatry, 20, 15–27.
2. 3 dopamine receptor. Journal of Receptors and Signal Transduction, 24, 117–130.
3. Arif, S. A., & Mitchell, M. M. (2011). Iloperidone: A new drug for the treatment of schizophrenia. American Journal of Health System Pharmacy, 68(4), 301–308.
4. Baldessarini, R. J., & Tarazi, F. I. (1996). Brain dopamine receptors: A primer on their current status, basic and clinical. Harvard Review of Psychiatry, 3(6), 301–325.
5. Baldessarini, R. J., & Tarazi, F. I. (2005). Pharmacotherapy of psychosis and mania. In L. L. Brunton, J. S. Lazo, & K. Parker (Eds.), Goodman and Gilman's the pharmacological basis of therapeutics (pp. 461–500). New York: McGraw-Hill Press.
6. Barr, A. M., Powell, S. B., Markou, A., & Geyer, M. A. (2006). Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology, 51, 457–465.
7. Beaulieu, J. M., & Gainetdinov, R. R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacological Reviews, 63(1), 182–217.
8. 2 receptor mRNA. Brain Research, 564(2), 203–219.
9. 2 dopamine receptor family agonists and antagonists: The effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. Journal of Neural Transmission, 104(4–5), 341–362.
10. Choi, Y. K., Adham, N., Kiss, B., Gyertyán, I., & Tarazi, F. I. (2014). Long-term effects of cariprazine exposure on dopamine receptor subtypes. CNS Spectrums, 19(3), 268–277.
11. Corbett, R., Griffiths, L., Shipley, J. E., Shukla, U., Strupczewski, J. T., Szczepanik, A. M., … Kongsamut, S. (1997). Iloperidone: Preclinical profile and early clinical evaluation. CNS Drug Reviews, 3(2), 120–147.
12. 1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology (Berl), 121(3), 323–327.
13. Florijn, W. J., Tarazi, F. I., & Creese, I. (1997). Dopamine receptor subtypes: Differential regulation after 8 months treatment with antipsychotic drugs. Journal of Pharmacology and Experimental Therapeutics, 280(2), 561–569.
14. Greene, W. H. (2000). Econometric analysis (4th ed., pp. 462–465). Upper Saddle River: Prentice Hall.
15. 1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl), 121, 309–316.
16. 5 receptors of rat and human brain. Neuroscience, 100(4), 689–699.
17. Kongsamut, S., Roehr, J. E., Cai, J., Hartman, H. B., Weissensee, P., Kerman, L. L., … Sandrasagra, A. (1996). Iloperidone binding to human and rat dopamine and 5-HT receptors. European Journal of Pharmacology, 317, 417–423.
18. 1 hippocampus. Biological Psychiatry, 31, 560–570.
19. 2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology, 13, 139–150.
20. 2A receptors in the rat brain. Journal of Neural Transmission, 107, 295–302.
21. Lavedan, C., Licamele, L., Volpi, S., Hamilton, J., Heaton, C., Mack, K., … Polymeropoulos, M. H. (2009). Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Molecular Psychiatry, 14(8), 804–819.
22. 2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacology, Biochemistry and Behavior, 45, 195–200.
23. Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014). Clinical pharmacology of atypical antipsychotics: An update. EXCLI Journal, 13, 1163–1191.
24. 2 dopamine receptor mRNAs in rat brain. Neuropsychopharmacology, 5(4), 231–242.
25. Meltzer, H. Y. (2013). Update on typical and atypical antipsychotic drugs. Annual Review of Medicine, 64, 393–406.
26. 2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming. Psychopharmacology (Berl), 102, 411–413.
27. Paxinos, G., & Watson, C. (1986). The rat brain in stereotaxic coordinates (2nd ed.). Sydney; Orlando: Academic Press.
28. Potkin, S. G., Litman, R. E., Torres, R., & Wolfgang, C. D. (2008). Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of Clinical Psychopharmacology, 28(2 Suppl 1), S4–S11.
29. Salimi, K., Jarskog, L. F., & Lieberman, J. A. (2009). Antipsychotic drugs for first-episode schizophrenia: A comparative review. CNS Drugs, 23(10), 837–855.
30. 1-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. Journal of Neurophysiology, 71, 515–528.
31. 3 receptor expression: Implications for neurodevelopmental psychiatric disorders. Neurotoxicity Research, 4(7–8), 671–678.
32. 2 antagonists with potential atypical antipsychotic activity: Antipsychotic profile of iloperidone (HP 873). Journal of Medicinal Chemistry, 38, 1119–1131.
33. Szewczak, M. R., Corbett, R., Rush, D. K., Wilmot, C. A., Conway, P. G., Strupczewski, J. T., & Cornfeldt, M. (1995). The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. Journal of Pharmacology and Experimental Therapeutics, 274(3), 1404–1413.
34. 4 dopamine receptors in fibroblast and dopaminergic cell lines. Journal of Pharmacology and Experimental Therapeutics, 268, 495–502.
35. 4 receptors in rat forebrain. NeuroReport, 8(16), 3423–3426.
36. Tarazi, F. I., Moran-Gates, T., Wong, E. H., Henry, B., & Shahid, M. (2008). Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl), 198(1), 103–111.
37. Tarazi, F. I., & Stahl, S. M. (2012). Iloperidone, asenapine and lurasidone: A primer on their current status. Expert Opinion on Pharmacotherapy, 13(13), 1911–1922.
38. 4-like dopamine receptors. Neuropsychopharmacology, 17(3), 186–196.
39. Tarazi, F. I., Zhang, K., & Baldessarini, R. J. (2001). Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment. Journal of Pharmacology and Experimental Therapeutics, 297(2), 711–717.
40. Tarsy, D., Baldessarini, R. J., & Tarazi, F. I. (2002). Effects of newer antipsychotics on extrapyramidal function. CNS Drugs, 16, 23–45.
41. Tek, C., Gold, J., Blaxton, T., Wilk, C., McMahon, R. P., & Buchanan, R. W. (2002). Visual perceptual and working memory impairments in schizophrenia. Archives of General Psychiatry, 59(2), 146–153.
42. Winer, B. J., Brown, D. R., & Michels, K. M. (1991). Statistical principles in experimental drug design (3rd ed., pp. 165–166). New York: McGraw Hill.
43. 3 receptors in rat brain: Selective protection by dopamine. Brain Research, 847(1), 32–37.